Triumph of Pneumococcal Conjugate Vaccines: Overcoming a Common Foe

Pneumococcal conjugate vaccine (PCV) has reduced the burden of pneumococcal disease by the near elimination of vaccine serotypes from countries giving a booster dose at >9 months of life. Herd protection, induced by interruption of pneumococcal vaccine type transmission has protected children too young to be immunized, children and adults with underlying risk conditions for invasive pneumococcal disease, and the elderly. PCV has rolled out in most poor countries, but millions of children remain un-immunized especially in middle income countries because of cost constraints. These are being met by considering fewer doses to maintain herd protection, and support for more affordable vaccine from developing country manufacturers. While 3rd generation PCV's with potential inclusion of 20+ serotypes are close to market in adults, it will be their introduction into childhood immunization and herd protection that is most likely to maximize the public health benefits of these vaccines.

Automated summary

Pneumococcal conjugate vaccine has successfully reduced the burden of disease and provided herd protection for those who cannot be vaccinated. While widely rolled out in poor countries, there are still many unvaccinated children in middle income countries. Solutions being considered include reducing doses and supporting more affordable vaccine sources.